| Literature DB >> 33808433 |
Raluca Cristina Mocanu1, Maria-Alexandra Martu2, Ionut Luchian2, Irina Georgeta Sufaru2, George Alexandru Maftei3, Nicoleta Ioanid4, Silvia Martu2, Monica Tatarciuc5.
Abstract
Fixed prosthodontic dental restorations can potentially affect the periodontal tissues and vice versa, the periodontium can influence the longevity and esthetic appearance of dental restorations. We proposed an investigation on total bacterial load, specific periodontal pathogens, and periodontal clinical parameters in patients with dental fixed prosthesis and different degrees of periodontal tissue loss that followed photoactivation therapy (PDT) adjunctive to scaling and root planing. The study was conducted on 160 subjects, which were randomly assigned to scaling and root planing (SRP) alone (52 subjects, 256 sites), SRP and chlorhexidine rinsing (58 subjects, 276 sites), and SRP plus PDT (50 subjects, 318 sites). Periodontal parameters (plaque index, bleeding on probing, probing depth, and clinical attachment loss), followed by total bacterial load and specific periodontal pathogens (Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola) were examined in each patient at baseline, one and six months after. PDT exerted significant improvements both in clinical and microbiological load after one month, and these results were maintained 6 months after when compared to chlorhexidine rinsing or SRP alone, especially in severe periodontitis cases. Photoactivation therapy as an adjunctive periodontal therapeutic method was efficient in offering supplementary periodontal improvements in the clinical and microbiological parameters of patients with fixed dental prosthesis, particularly in severe periodontitis cases.Entities:
Keywords: bacteria; chlorhexidine; dental bridges; edentation treatment; periodontitis; photoactivation therapy; scaling and root planing
Year: 2021 PMID: 33808433 PMCID: PMC8065635 DOI: 10.3390/microorganisms9040713
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Sequence of primers and probes.
| Patogen | Primer 5′→3′ | Probe 5′→3′ | Gene |
|---|---|---|---|
|
| F: GCGAACGTTAGCGTTTTAC | ATTGCCCGCACCGAAACCCAAC | waaA |
|
| F: TGGTTTCATGCAGCTTCTT | GTACCTCATATCCCGAGGGGCTG | waaA |
|
| F: CCTTGAACAAAAACCGGAA | GAGCTCTGAATAATTTTGATGCA | waaG |
|
| F: CTCGCTCGGTGAGTTTGAA | CGATTCGCAAGCGTTATCCCGACT | waaA |
A. a = Aggregatibacter actinomycetemcomitan; P. g = Porphyromonas gingivalis; T. d = Treponema denticola; T. f = Tannerella forsythia.
General characteristics of study subjects.
| Group | Periodontitis Severity | Number of Subjects | Sites | Age (Years) (Mean ± SD) | Gender (%) | |
|---|---|---|---|---|---|---|
| Male | Female | |||||
| PDT | S1 | 14 | 79 (9.29%) | 47.3 ± 7.4 | 42.8 | 57.2 |
| S2 | 16 | 97 (11.41%) | 52.5 ± 10.2 | 50.5 | 49.5 | |
| S3 | 10 | 68 (8.00%) | 53.1 ± 10.1 | 60.0 | 40 | |
| S4 | 10 | 74 (8.71%) | 47.9 ± 9.6 | 75.0 | 25 | |
| CHX | S1 | 18 | 75 (8.82%) | 45.3 ± 7.9 | 66.7 | 33.3 |
| S2 | 10 | 67 (7.88%) | 47.5 ± 7.6 | 60.0 | 40 | |
| S3 | 16 | 71 (8.35%) | 57.2 ± 11.9 | 62.5 | 37.5 | |
| S4 | 14 | 63 (7.41%) | 50.3 ± 12.4 | 71.4 | 28.6 | |
| Control | S1 | 8 | 51 (6.00%) | 46.9 ± 8.8 | 50.0 | 50.0 |
| S2 | 14 | 74 (8.71%) | 52.1 ± 10.8 | 42.8 | 57.2 | |
| S3 | 16 | 77 (9.07%) | 50.8 ± 11.4 | 50.0 | 50 | |
| S4 | 14 | 54 (6.35%) | 49.2 ± 8.6 | 57.1 | 42.9 | |
PDT: SRP + photoactivation therapy group; CHX: SRP + chlorhexidine rinsing group; SD: standard deviation. S1: Periodontitis stage 1; S2: Periodontitis stage 2; S3: Periodontitis stage 3; S4: Periodontitis stage 4.
Periodontal parameters on study groups and periodontitis severity at baseline, one month and six months evaluation.
| Parameter | PDT | CHX | Control | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S1 | S2 | S3 | S4 | S1 | S2 | S3 | S4 | S1 | S2 | S3 | S4 | |
| Baseline evaluation | ||||||||||||
| PI (+)(%) | 98.7 | 97.9 | 95.6 | 92.6 | 98.7 | 94.0 | 95.8 | 90.5 | 96.0 | 97.3 | 92.2 | 92.6 |
| BOP (+)(%) | 87.3 | 85.6 | 89.7 | 93.2 | 89.3 | 88.1 | 87.3 | 85.7 | 86.3 | 91.9 | 91.0 | 87.0 |
| PD (Mean ±DS) | 3.24± 0.42 | 4.40± 0.21 | 5.21± 1.93 | 7.20 ± 1.18 | 3.21± 0.74 | 4.20± 0.95 | 5.18± 1.27 | 7.50± 1.72 | 3.01± 0.79 | 4.10 ± 1.13 | 5.15 ± 1.87 | 6.90 ± 1.41 |
| CAL (Mean± DS) | 1.40 ± 0.32 | 3.50 ± 0.44 | 4.22 ± 0.42 | 5.68 ± 1.16 | 1.61 ± 0.28 | 3.23 ± 0.33 | 4.48 ± 0.99 | 5.90 ± 1.24 | 1.42 ± 0.78 | 3.19 ± 0.32 | 4.21 ± 1.31 | 5.41 ± 1.75 |
| One month evaluation | ||||||||||||
| PI (+)(%) | 5.1 * | 6.2 * | 3.0 * | 8.1 * | 1.3 * | 7.5 * | 11.2 * | 12.7 * | 4.0 * | 8.1 * | 7.8 * | 7.4 * |
| BOP (+)(%) | 2.5 * | 2.1 * | 1.5 * | 4.1 * | 4.0 * | 3.0 * | 5.7 * | 9.5 * | 13.7 * | 12.2 * | 31.6 | 42.2 |
| PD (Mean± SD) | 1.98 ± 0.31 * | 2.21 ± 0.22 * | 3.87 ± 0.41 * | 5.42 ± 0.84 * | 1.87 ± 0.63 * | 3.12 ± 0.32 * | 4.99 ± 0.55 | 6.62 ± 0.41 | 1.95 ± 0.1 * | 3.72 ± 0.88 | 5.01 ± 1.16 | 6.39 ± 1.23 |
| CAL (Mean± SD) | 1.12 ± 0.42 * | 1.81 ± 0.21 * | 2.03 ± 0.35 * | 4.32 ± 1.63 * | 1.13 ± 0.17 * | 2.67 ± 0.43 * | 4.21 ± 1.17 | 5.22 ± 1.73 | 0.82 ± 0.24 * | 2.93 ± 0.52 | 4.19 ± 1.16 | 5.40 ± 1.97 |
| Six months evaluation | ||||||||||||
| PI (+)(%) | 4.2 * | 4.7 * | 2.6 * | 7.2 * | 3.6 * | 9.6 * | 12.5 * | 14.2 * | 15.3 * | 14.9 * | 16.5 * | 17.2 * |
| BOP (+)(%) | 1.3 * | 1.7 * | 1.2 * | 2.5 * | 23.7 * | 26.9 * | 43.6 | 61.7 | 39.42 | 38.3 | 42.8 | 57.1 |
| PD (Mean± SD) | 1.61 ± 0.37 * | 1.82 ± 1.41 * | 3.34 ± 1.66 * | 5.23 ± 1.92 * | 2.02 ± 1.14 * | 3.51 ± 1.42 * | 5.29 ± 1.90 | 6.97 ± 2.46 | 3.05 ± 1.53 | 4.61 ± 2.07 | 5.56 ± 2.44 | 7.19 ± 2.88 |
| CAL (Mean± SD) | 0.95 ± 0.14 * | 1.34 ± 0.27 * | 1.88 ± 0.41 * | 4.75 ± 2.63 * | 1.27 ± 0.43 * | 2.93 ± 0.63 * | 4.65 ± 1.04 | 5.98 ± 1.48 | 1.24 ± 0.41 | 3.46 ± 0.73 | 4.91 ± 1.77 | 6.22 ± 2.24 |
PDT: SRP + photoactivation therapy group; CHX: SRP + chlorhexidine rinsing group; SD: standard deviation. S1: Periodontitis stage 1; S2: Periodontitis stage 2; S3: Periodontitis stage 3; S4: Periodontitis stage 4. PI: Plaque index; BOP: Bleeding on probing index; PD: periodontal probing depth; CAL: clinical attachment loss; SD: standard deviation. * p < 0.05 was considered statistically significant.
Total bacterial load at baseline and at after treatment (one month and six months) in the PDT group.
| Stage | Baseline | At One Month | At 6 Months | ||
|---|---|---|---|---|---|
| S1 | 5.4 × 106 (2.6 × 104–8.3 × 108) | 1.6 × 103 (9.5 × 102–8.9 × 104) * | 5.2 × 103 (1.2 × 102–7.5 × 105) * | ||
| S2 | 1.6 × 107 (3.8 × 106–5.2 × 109) | 9.6 × 103 (6.2 × 102–9.2 × 104) * | 1.7 × 104 (9.1 × 102–9.6 × 105) * | ||
| S3 | 3.2 × 108 (6.8 × 106–9.8 × 109) | 6.9 × 104 (1.4 × 103–8.1 × 107) * | 1.4 × 105 (2.7 × 103–8.3 × 107) * | ||
| S4 | 8.3 × 108 (5.2 × 106–9.3 × 109) | 8.5 × 104 (2.5 × 103–1.2 × 107) * | 1.8 × 105 (5.5 × 103–5.3 × 107) * | ||
PDT: SRP + photoactivation therapy group; S1: Periodontitis stage 1; S2: Periodontitis stage 2; S3: Periodontitis stage 3; S4: Periodontitis stage 4. Data are expressed as median (minimum-maximum). * p < 0.05; comparison between the evaluation at baseline and at one and 6 months in the same group.
Total bacterial load at baseline and at after treatment (one month and six months) in CHX group.
| Stage | Baseline | At One Month | At 6 Months |
|---|---|---|---|
| S1 | 5.6 × 106 (6.2 × 104–7.5 × 108) | 8.4 × 104 (5.5 × 102–2.1 × 106) * | 3.7 × 105 (9.1 × 102–9.2 × 106) *° |
| S2 | 1.9 × 107 (4.6 × 106–9.2 × 109) | 0.5 × 104 (7.8 × 102–6.3 × 106) * | 6.2 × 105 (9.3 × 102–8.7 × 106) *° |
| S3 | 3.6 × 108 (6.5 × 106–9.1 × 109) | 9.1 × 107 (2.9 × 103–0.1 × 109) ° | 1.8 × 108 (7.4 × 105–7.5 × 109) ° |
| S4 | 7.9 × 108 (2.9 × 106–8.3 × 109) | 0.3 × 108 (1.8 × 105–2.3 × 109) ° | 6.2 × 108 (5.9 × 105–8.4 × 109) ° |
CHX: SRP + chlorhexidine rinsing group. S1: Periodontitis stage 1; S2: Periodontitis stage 2; S3: Periodontitis stage 3; S4: Periodontitis stage 4. Data are expressed as median (minimum–maximum). * p < 0.05; comparison between the evaluation at baseline and at one and 6 months in the same group; ° p < 0.05; comparison between groups at the same evaluation time.
Total bacterial load at baseline and at after treatment (one month and six months) in control group (SRP only).
| Stage | Baseline | At One Month | At 6 Months |
|---|---|---|---|
| S1 | 4.9 × 106 (1.6 × 104–2.3 × 108) | 0.3 × 106 (1.5 × 104–1.2 × 108) ° | 5.1 × 106 (5.5 × 104–4.7 × 108) ° |
| S2 | 1.7 × 107 (7.1 × 106–8.1 × 108) | 0.2 × 107 (1.5 × 106–6.4 × 108) ° | 2.3 × 107 (5.9 × 106–7.8 × 108) ° |
| S3 | 3.1 × 108 (6.3 × 106–8.8 × 109) | 2.1 × 108 (5.2 × 106–7.3 × 109) ° | 2.7 × 109 (7.9 × 107–9.1 × 109) †° |
| S4 | 7.8 × 108 (6.5 × 106–8.1 × 109) | 6.6 × 108 (4.2 × 106–5.3 × 109) ° | 8.7 × 109 (8.8 × 108–9.8 × 109) †° |
S1: Periodontitis stage 1; S2: Periodontitis stage 2; S3: Periodontitis stage 3; S4: Periodontitis stage 4. Data are expressed as median (minimum-maximum). † p < 0.05; comparison between the evaluation at baseline and at one and 6 months in the same group with significant increase. ° p < 0.05; comparison between groups at the same evaluation time.
Periodontal pathogens detection at baseline and after treatment (one month and six months) for the PDT group.
| Pathogen | Stage | Baseline | At One Month | At 6 Months |
|---|---|---|---|---|
|
| S1 | 0.0 | 0.0 | 0.0 |
| S2 | 2.1 | 0.0 a | 0.0 a | |
| S3 | 30.9 | 1.4 b | 2.9 b | |
| S4 | 33.8 | 2.7 b | 5.4 b | |
|
| S1 | 6.3 | 0.0 b | 1.3 b |
| S2 | 14.4 | 0.0 b | 2.1 b | |
| S3 | 63.2 | 4.4 b | 10.3 b | |
| S4 | 83.8 | 6.7 b | 10.9 b | |
|
| S1 | 30.4 | 0.0 b | 2.5 b |
| S2 | 32.9 | 4.1 b | 6.2 b | |
| S3 | 67.6 | 8.8 b | 10.3 b | |
| S4 | 93.2 | 8.1 b | 12.2 b | |
|
| S1 | 22.8 | 2.5 b | 3.8 b |
| S2 | 29.9 | 2.1 b | 5.1 b | |
| S3 | 57.4 | 5.8 b | 7.3 b | |
| S4 | 66.2 | 8.1 b | 10.8 b |
PDT: photoactivation therapy group; S1: Periodontitis stage 1; S2: Periodontitis stage 2; S3: Periodontitis stage 3; S4: Periodontitis stage 4. Results are expressed as percentages. a p < 0.005; b p < 0.001; comparison between the evaluation at baseline and at one and 6 months in the same group.
Periodontal pathogens detection at baseline and after treatment (one month and six months) for the CHX group.
| Pathogen | Stage | Baseline | At One Month | At 6 Months |
|---|---|---|---|---|
|
| S1 | 0.0 | 0.0 | 0.0 |
| S2 | 2.9 | 1.2 | 1.5 | |
| S3 | 26.8 | 14.1 a | 23.9 | |
| S4 | 30.1 | 19.1 | 22.2 | |
|
| S1 | 9.3 | 4.0 c | 8.0 |
| S2 | 16.4 | 5.9 c | 13.4 | |
| S3 | 63.4 | 30.9 c | 47.9 | |
| S4 | 85.7 | 30.2 c | 71.8 | |
|
| S1 | 34.7 | 4.0 c | 14.7 b |
| S2 | 37.3 | 4.5 c | 32.8 | |
| S3 | 57.7 | 32.4 | 47.9 | |
| S4 | 85.7 | 69.8 | 73.0 | |
|
| S1 | 22.7 | 1.3 c | 21.6 |
| S2 | 32.8 | 4.5 c | 29.8 | |
| S3 | 54.9 | 36.7 | 43.7 | |
| S4 | 73.0 | 55.5 | 72.2 |
CHX: Chlorhexidine rinsing group; S1: Periodontitis stage 1; S2: Periodontitis stage 2; S3: Periodontitis stage 3; S4: Periodontitis stage 4. Results are expressed as percentages. a p < 0.05; b p < 0.005; c p < 0.001; comparison between the evaluation at baseline and at one and 6 months in the same group.
Periodontal pathogens detection at baseline and after treatment (one month and six months) for the control group.
| Pathogen | Stage | Baseline | At One Month | At 6 Months |
|---|---|---|---|---|
|
| S1 | 0.0 | 0.0 | 0.0 |
| S2 | 4.1 | 2.7 | 2.7 | |
| S3 | 28.6 | 22.1 | 24.7 | |
| S4 | 35.2 | 29.6 | 31.5 | |
|
| S1 | 9.8 | 3.9 b | 7.8 |
| S2 | 17.6 | 8.1 b | 13.5 | |
| S3 | 62.3 | 45.5 | 51.9 | |
| S4 | 81.4 | 66.7 | 74.1 | |
|
| S1 | 33.3 | 13.7 a | 27.4 |
| S2 | 39.2 | 27.0 | 29.7 | |
| S3 | 76.6 | 57.1 | 67.3 | |
| S4 | 90.7 | 77.8 | 85.9 | |
|
| S1 | 19.6 | 5.9 b | 17.7 |
| S2 | 28.4 | 14.9 a | 25.7 | |
| S3 | 58.4 | 41.6 | 44.1 | |
| S4 | 74.1 | 57.4 | 66.7 |
S1: Periodontitis stage 1; S2: Periodontitis stage 2; S3: Periodontitis stage 3; S4: Periodontitis stage 4. Results are expressed as percentages. a p < 0.005; b p < 0.001; comparison between the evaluation at baseline and at one and 6 months in the same group.